Tempest Therapeutics Makes Strides in 2024 Financial Year
Tempest Therapeutics, Inc. (NASDAQ: TPST), a pioneering clinical-stage biotechnology company, has recently shared its financial outcomes for the year 2024, alongside key updates on its business endeavors. Known for developing targeted and immune-mediated therapeutics for cancer, Tempest has impressive achievements to report.
Significant Awards and Collaborations
Tempest's progress in 2024 was marked by noteworthy recognitions, including both Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA) for its innovative treatment, Amezalpat (TPST-1120). This drug targets Hepatocellular Carcinoma (HCC), a common form of liver cancer. Furthermore, Tempest achieved a partnership with Roche to advance Amezalpat in combination therapy into a pivotal Phase 3 clinical trial—an essential step for the potential first-line treatment of HCC.
Amezalpat (TPST-1120) Development Journey
In the clinical landscape, Amezalpat has demonstrated impressive outcomes, including positive survival data through a randomized Phase 1b/2 study revealing a six-month improvement in median overall survival when combined with standard treatments. The collaboration with Roche propels this drug into further clinical evaluation, embodying a significant opportunity for patient care advancement in liver cancer management.
Advancements with TPST-1495
Alongside Amezalpat, Tempest has not overlooked its second clinical program: TPST-1495. This dual EP2/4 prostaglandin receptor antagonist also received FDA's clearance to commence a Phase 2 trial aimed at treating Familial Adenomatous Polyposis (FAP), indicating a robust portfolio focused on diverse therapeutic areas.
Corporate Growth and Strategic Focus
Throughout the year, Tempest reinforced its leadership team to further enhance its clinical knowledge base in preparation for upcoming trials and beyond. The appointments of Troy M. Wagner as Vice President of Quality Assurance and Sheldon Mullins as Vice President of Regulatory Affairs signify the company's dedication to solidifying its operational foundation.
Financial Updates and Insights
For the fiscal year, Tempest reported a decrease in cash reserves, ending with approximately $30.3 million in cash and equivalents compared to $39.2 million the previous year. This reduction was chiefly due to expenditures associated with research and development efforts, which rose to $28.5 million, primarily due to preparations for the pivotal trials.
The net loss for the year amounted to $41.8 million, translating to a net loss per share of $1.50. This compares unfavorably to the prior year but reflects the company's robust investment in advancing its clinical programs and potential treatments. General and administrative expenses also saw an increase, reflecting enhanced operational activity and necessary expansion.
Looking Ahead: Future Goals
Looking forward, Tempest plans to expedite Amezalpat through a registrational study focusing on first-line liver cancer patients, contingent on further resource acquisition. Additionally, a Phase 2 trial for TPST-1495 is set to take place, aimed for 2025 initiation, backed by the Cancer Prevention Clinical Trials Network and the National Cancer Institute.
About Tempest Therapeutics
At the core of Tempest's mission is a commitment to innovation in cancer therapies. With a diverse pipeline of promising small molecule product candidates, Tempest is dedicated to developing groundbreaking treatments that can significantly improve patient outcomes across various malignancies. As the company navigates through this dynamic landscape, it remains steadfast in its focus on impactful scientific research and patient care.
Frequently Asked Questions
What key designations did Tempest achieve in 2024?
Tempest received both Orphan Drug and Fast Track designations from the FDA for Amezalpat, recognizing its potential for treating HCC.
What unique collaboration did Tempest announce?
Tempest entered into a partnership with Roche to advance Amezalpat into a pivotal trial for first-line treatment of HCC.
How did Tempest's financials look in 2024?
The company reported a net loss of $41.8 million, with cash reserves dropping to $30.3 million by the end of the fiscal year.
What is the future direction for TPST-1495?
Tempest aims to initiate a Phase 2 study for TPST-1495 targeting Familial Adenomatous Polyposis in 2025.
Where is Tempest Therapeutics headquartered?
Tempest is based in Brisbane, California, focusing on innovative cancer therapies.
